Global Recombinant Humanized Collagen 麻豆原创 Growth 2025-2031

Publication ID:

LPI08251631

Publication Date:

August 4, 2025

Pages:

105

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Humanized Collagen market size is predicted to grow from US$ 104 million in 2025 to US$ 2560 million in 2031; it is expected to grow at a CAGR of 70.6% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Recombinant humanized collagen refers to the introduction of collagen sequences encoded by human genes into cells for expression and production through gene recombination technology to obtain proteins with the same or similar structural and biological characteristics as natural collagen. Recombinant humanized collagen has many advantages, such as controllable production process, high purity, non-infectiousness, etc. It has a wide range of application prospects in medicine, biotechnology, cosmetics and other fields. Recombinant humanized collagen can be used as a biological material in tissue repair and regenerative medicine, including muscles, bones, soft tissues, etc. In addition, it can also be used as a drug carrier for sustained-release drugs, such as heparin, thiazolidinone, etc., to improve the stability and bioavailability of the drug. At the same time, it can also be used to produce medical devices and medical materials such as artificial skin and artificial cornea. Recombinant humanized collagen can be used in cell culture, gene transfection, vaccine production and other aspects. It can act as a scaffold or matrix in cell culture and gene transfection, improve cell adhesion and proliferation, and promote the development of tissue engineering and stem cell research. In terms of vaccine production, recombinant humanized collagen can be used as a vaccine carrier to improve the immunogenicity and efficacy of the vaccine. Recombinant humanized collagen can be used as an ingredient for efficient anti-wrinkle, moisturizing and skin repair, and is widely used in skin care products, makeup and other products. Recombinant humanized collagen has the same amino acid sequence and tertiary structure as natural collagen, which can act directly on the skin, promote the regeneration and repair of skin cells, and improve the elasticity and gloss of the skin.The Medical Device Standard Management Center of the State Food and Drug Administration issued an interpretation of the "Guiding Principles for the Naming of Recombinant Collagen Biomaterials", which divides recombinant humanized collagen into two types, type A and type B based on whether it contains non-human collagen amino acid sequences. Type A refers to materials that do not contain non-human collagen amino acid sequences, including full-length amino acid sequences encoded by human collagen specific type genes (without triple helical structure), or partial amino acid sequence fragments encoded by human collagen specific type genes, or a combination of human collagen functional fragments (the amino acid sequences do not contain non-human collagen amino acid sequences such as linking amino acids and tag amino acids). Type B refers to the material that adds non-human collagen amino acid sequences such as amino acids and tag amino acids based on the combination of human collagen functional fragments.
Compared with animal-derived collagen, recombinant collagen has a series of obvious advantages, including higher biological activity and biocompatibility, lower immunogenicity, lower risk of missed pathogens, better water solubility, non-cytotoxicity, and can be further processed and optimized. In addition, the denaturing temperature of recombinant collagen exceeds 72掳C, which is much higher than 40掳C for animal-derived collagen, which makes it more stable during transportation and storage. Therefore, as a safer material, recombinant collagen is more suitable for beauty and health products. With the advancement of the industry and the development of technology, its popularity and market penetration are gradually increasing. According to the "Guiding Principles for the Naming of Recombinant Collagen Biomaterials", recombinant collagen is divided into three main categories: recombinant human collagen, recombinant humanized collagen and recombinant collagen. The core differences in these three types of recombinant collagen are reflected in the construction of expression systems, host selection, protein expression, etc. As the homologous and similarity of gene sequences increases, the expression efficiency and biological activity function of collagen vectors will also be improved accordingly.
The 鈥淩ecombinant Humanized Collagen Industry Forecast鈥� looks at past sales and reviews total world Recombinant Humanized Collagen sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Humanized Collagen sales for 2025 through 2031. With Recombinant Humanized Collagen sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Humanized Collagen industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Humanized Collagen landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Humanized Collagen portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Humanized Collagen market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Humanized Collagen and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Humanized Collagen.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Humanized Collagen market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Type A
Type B
Segmentation by Application:
Medicine
Biotechnology
Cosmetics
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Giant Biogene
Shanxi Jinbo Bio-Pharmaceutical
Jiangsu JLand Biotech
Jiangsu Chuangjian Medical Technology
Evonik
ProColl
CollPlant
Creative BioMart
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Humanized Collagen market?
What factors are driving Recombinant Humanized Collagen market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Humanized Collagen market opportunities vary by end market size?
How does Recombinant Humanized Collagen break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Recombinant Humanized Collagen Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Recombinant Humanized Collagen by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Recombinant Humanized Collagen by Country/Region, 2020, 2024 & 2031
2.2 Recombinant Humanized Collagen Segment by Type
2.2.1 Type A
2.2.2 Type B
2.3 Recombinant Humanized Collagen Sales by Type
2.3.1 Global Recombinant Humanized Collagen Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global Recombinant Humanized Collagen Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global Recombinant Humanized Collagen Sale Price by Type (2020-2025)
2.4 Recombinant Humanized Collagen Segment by Application
2.4.1 Medicine
2.4.2 Biotechnology
2.4.3 Cosmetics
2.4.4 Other
2.5 Recombinant Humanized Collagen Sales by Application
2.5.1 Global Recombinant Humanized Collagen Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global Recombinant Humanized Collagen Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global Recombinant Humanized Collagen Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Recombinant Humanized Collagen Breakdown Data by Company
3.1.1 Global Recombinant Humanized Collagen Annual Sales by Company (2020-2025)
3.1.2 Global Recombinant Humanized Collagen Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global Recombinant Humanized Collagen Annual Revenue by Company (2020-2025)
3.2.1 Global Recombinant Humanized Collagen Revenue by Company (2020-2025)
3.2.2 Global Recombinant Humanized Collagen Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global Recombinant Humanized Collagen Sale Price by Company
3.4 Key Manufacturers Recombinant Humanized Collagen Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Humanized Collagen Product Location Distribution
3.4.2 Players Recombinant Humanized Collagen Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Recombinant Humanized Collagen by Geographic Region
4.1 World Historic Recombinant Humanized Collagen 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global Recombinant Humanized Collagen Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Recombinant Humanized Collagen Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Recombinant Humanized Collagen 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global Recombinant Humanized Collagen Annual Sales by Country/Region (2020-2025)
4.2.2 Global Recombinant Humanized Collagen Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Humanized Collagen Sales Growth
4.4 APAC Recombinant Humanized Collagen Sales Growth
4.5 Europe Recombinant Humanized Collagen Sales Growth
4.6 Middle East & Africa Recombinant Humanized Collagen Sales Growth
5 Americas
5.1 Americas Recombinant Humanized Collagen Sales by Country
5.1.1 Americas Recombinant Humanized Collagen Sales by Country (2020-2025)
5.1.2 Americas Recombinant Humanized Collagen Revenue by Country (2020-2025)
5.2 Americas Recombinant Humanized Collagen Sales by Type (2020-2025)
5.3 Americas Recombinant Humanized Collagen Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Humanized Collagen Sales by Region
6.1.1 APAC Recombinant Humanized Collagen Sales by Region (2020-2025)
6.1.2 APAC Recombinant Humanized Collagen Revenue by Region (2020-2025)
6.2 APAC Recombinant Humanized Collagen Sales by Type (2020-2025)
6.3 APAC Recombinant Humanized Collagen Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Humanized Collagen by Country
7.1.1 Europe Recombinant Humanized Collagen Sales by Country (2020-2025)
7.1.2 Europe Recombinant Humanized Collagen Revenue by Country (2020-2025)
7.2 Europe Recombinant Humanized Collagen Sales by Type (2020-2025)
7.3 Europe Recombinant Humanized Collagen Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Humanized Collagen by Country
8.1.1 Middle East & Africa Recombinant Humanized Collagen Sales by Country (2020-2025)
8.1.2 Middle East & Africa Recombinant Humanized Collagen Revenue by Country (2020-2025)
8.2 Middle East & Africa Recombinant Humanized Collagen Sales by Type (2020-2025)
8.3 Middle East & Africa Recombinant Humanized Collagen Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Humanized Collagen
10.3 Manufacturing Process Analysis of Recombinant Humanized Collagen
10.4 Industry Chain Structure of Recombinant Humanized Collagen
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Humanized Collagen Distributors
11.3 Recombinant Humanized Collagen Customer
12 World Forecast Review for Recombinant Humanized Collagen by Geographic Region
12.1 Global Recombinant Humanized Collagen 麻豆原创 Size Forecast by Region
12.1.1 Global Recombinant Humanized Collagen Forecast by Region (2026-2031)
12.1.2 Global Recombinant Humanized Collagen Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Recombinant Humanized Collagen Forecast by Type (2026-2031)
12.7 Global Recombinant Humanized Collagen Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Giant Biogene
13.1.1 Giant Biogene Company Information
13.1.2 Giant Biogene Recombinant Humanized Collagen Product Portfolios and Specifications
13.1.3 Giant Biogene Recombinant Humanized Collagen Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Giant Biogene Main Business Overview
13.1.5 Giant Biogene Latest Developments
13.2 Shanxi Jinbo Bio-Pharmaceutical
13.2.1 Shanxi Jinbo Bio-Pharmaceutical Company Information
13.2.2 Shanxi Jinbo Bio-Pharmaceutical Recombinant Humanized Collagen Product Portfolios and Specifications
13.2.3 Shanxi Jinbo Bio-Pharmaceutical Recombinant Humanized Collagen Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Shanxi Jinbo Bio-Pharmaceutical Main Business Overview
13.2.5 Shanxi Jinbo Bio-Pharmaceutical Latest Developments
13.3 Jiangsu JLand Biotech
13.3.1 Jiangsu JLand Biotech Company Information
13.3.2 Jiangsu JLand Biotech Recombinant Humanized Collagen Product Portfolios and Specifications
13.3.3 Jiangsu JLand Biotech Recombinant Humanized Collagen Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Jiangsu JLand Biotech Main Business Overview
13.3.5 Jiangsu JLand Biotech Latest Developments
13.4 Jiangsu Chuangjian Medical Technology
13.4.1 Jiangsu Chuangjian Medical Technology Company Information
13.4.2 Jiangsu Chuangjian Medical Technology Recombinant Humanized Collagen Product Portfolios and Specifications
13.4.3 Jiangsu Chuangjian Medical Technology Recombinant Humanized Collagen Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Jiangsu Chuangjian Medical Technology Main Business Overview
13.4.5 Jiangsu Chuangjian Medical Technology Latest Developments
13.5 Evonik
13.5.1 Evonik Company Information
13.5.2 Evonik Recombinant Humanized Collagen Product Portfolios and Specifications
13.5.3 Evonik Recombinant Humanized Collagen Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Evonik Main Business Overview
13.5.5 Evonik Latest Developments
13.6 ProColl
13.6.1 ProColl Company Information
13.6.2 ProColl Recombinant Humanized Collagen Product Portfolios and Specifications
13.6.3 ProColl Recombinant Humanized Collagen Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 ProColl Main Business Overview
13.6.5 ProColl Latest Developments
13.7 CollPlant
13.7.1 CollPlant Company Information
13.7.2 CollPlant Recombinant Humanized Collagen Product Portfolios and Specifications
13.7.3 CollPlant Recombinant Humanized Collagen Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 CollPlant Main Business Overview
13.7.5 CollPlant Latest Developments
13.8 Creative BioMart
13.8.1 Creative BioMart Company Information
13.8.2 Creative BioMart Recombinant Humanized Collagen Product Portfolios and Specifications
13.8.3 Creative BioMart Recombinant Humanized Collagen Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Creative BioMart Main Business Overview
13.8.5 Creative BioMart Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.